ATE347550T1 - Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure - Google Patents

Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure

Info

Publication number
ATE347550T1
ATE347550T1 AT02724323T AT02724323T ATE347550T1 AT E347550 T1 ATE347550 T1 AT E347550T1 AT 02724323 T AT02724323 T AT 02724323T AT 02724323 T AT02724323 T AT 02724323T AT E347550 T1 ATE347550 T1 AT E347550T1
Authority
AT
Austria
Prior art keywords
alpha
polymorphous
ethoxyethyl
benzimidazole
piperidinyl
Prior art date
Application number
AT02724323T
Other languages
English (en)
Inventor
Venero Aurelio Orjales
Martin Maravillas Bordell
Mori Gonzalo Canal
Fuente Haydee Blanco
De Pablo Maria Luisa Lucero
Royo Victor Rubio
Pestana Ramon Mosquera
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE347550(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Application granted granted Critical
Publication of ATE347550T1 publication Critical patent/ATE347550T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02724323T 2002-04-19 2002-04-19 Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure ATE347550T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000194 WO2003089425A1 (es) 2002-04-19 2002-04-19 POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO

Publications (1)

Publication Number Publication Date
ATE347550T1 true ATE347550T1 (de) 2006-12-15

Family

ID=29225789

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02724323T ATE347550T1 (de) 2002-04-19 2002-04-19 Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure

Country Status (31)

Country Link
US (2) US7612095B2 (de)
EP (1) EP1505066B1 (de)
JP (1) JP5142448B2 (de)
KR (1) KR100673140B1 (de)
CN (1) CN1290843C (de)
AR (1) AR039423A1 (de)
AT (1) ATE347550T1 (de)
AU (1) AU2002255017B2 (de)
BG (1) BG66302B1 (de)
BR (1) BRPI0215703B8 (de)
CA (1) CA2484460C (de)
CY (2) CY1107564T1 (de)
CZ (1) CZ305162B6 (de)
DE (1) DE60216641T2 (de)
DK (1) DK1505066T3 (de)
ES (1) ES2278018T3 (de)
HK (1) HK1072772A1 (de)
HR (1) HRP20041048B1 (de)
HU (1) HU230032B1 (de)
IL (1) IL164645A (de)
MX (1) MXPA04010313A (de)
NO (1) NO329327B1 (de)
NZ (1) NZ536551A (de)
PA (1) PA8571201A1 (de)
PE (1) PE20040086A1 (de)
PT (1) PT1505066E (de)
SI (1) SI1505066T1 (de)
SK (1) SK288052B6 (de)
UA (1) UA76866C2 (de)
UY (1) UY27762A1 (de)
WO (1) WO2003089425A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
WO2013001731A1 (ja) * 2011-06-30 2013-01-03 パナソニック株式会社 通信システム、ユーザ端末並びに通信装置
CN102675101B (zh) * 2012-05-16 2014-01-29 王蕾 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法
CZ307500B6 (cs) 2012-08-15 2018-10-24 Zentiva, K.S. Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty
CN103214454A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 一种比拉斯汀晶型及制备方法
WO2014188453A2 (en) * 2013-05-24 2014-11-27 Msn Laboratories Private Limited Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
CN103356616A (zh) * 2013-06-29 2013-10-23 北京万全德众医药生物技术有限公司 一种含有比拉斯汀的药物组合物及其制备方法
CN104447682A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 比拉斯汀化合物
CN104398481A (zh) * 2014-10-29 2015-03-11 万全万特制药江苏有限公司 比拉斯汀口崩片及其制备方法
CN107849007A (zh) * 2015-07-24 2018-03-27 乌奎玛公司 比拉斯汀的晶型及其制备方法
EP3170816A1 (de) * 2015-11-20 2017-05-24 Faes Farma, S.A. Übersättigte zusammensetzungen von benzimidazolverbindungen
EP3170817A1 (de) * 2015-11-20 2017-05-24 Faes Farma, S.A. Cokristalle von benzimidazolverbindungen
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine
EP3452462A4 (de) * 2016-05-05 2019-10-23 MSN Laboratories Private Limited, R&D Center Feststoffformen von 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methyl-propansäure und verfahren zur herstellung davon
EP3453384B1 (de) 2017-09-07 2020-05-27 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmazeutische tablette enhaltend bilastin
EP3641735B1 (de) 2017-12-18 2021-02-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmazeutische tablettenzusammensetzung mit bilastinform 3 und wasserlöslichem füllstoff
ES2835287T3 (es) 2017-12-18 2021-06-22 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica de comprimido que comprende la forma polimórfica 3 de bilastina y aluminometasilicato de magnesio
LT3740191T (lt) 2018-01-18 2021-08-10 Faes Farma, S.A. Oftalmologinės kompozicijos, apimančios bilastiną, beta-ciklodekstriną ir bent vieną gelinimo agentą
EP4267109A1 (de) 2020-12-23 2023-11-01 Noucor Health S.A. Nichtmikronisierte bilastinzusammensetzung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
TR200103851T2 (tr) * 1999-04-16 2002-04-22 Dr. Reddy' S Research Foundation Bir antidiyabetik maddenin yeni polimorfik formları, bunların hazırlanması için işlem ve bunları farmasötik bileşimler
ATE246191T1 (de) * 1999-04-23 2003-08-15 Smithkline Beecham Plc Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz

Also Published As

Publication number Publication date
DE60216641T2 (de) 2007-09-27
US20050203141A1 (en) 2005-09-15
HRP20041048B1 (hr) 2013-04-30
HRP20041048A9 (hr) 2013-01-31
SI1505066T1 (sl) 2007-04-30
CA2484460A1 (en) 2003-10-30
PA8571201A1 (es) 2003-12-10
HU230032B1 (hu) 2015-05-28
CN1290843C (zh) 2006-12-20
KR20050005448A (ko) 2005-01-13
HUP0500241A2 (hu) 2005-06-28
US7612095B2 (en) 2009-11-03
SK50202004A3 (sk) 2005-05-05
CN1628112A (zh) 2005-06-15
BRPI0215703B1 (pt) 2017-06-27
PT1505066E (pt) 2007-03-30
UY27762A1 (es) 2003-09-30
US20100004285A1 (en) 2010-01-07
CA2484460C (en) 2009-09-29
NZ536551A (en) 2006-08-31
CY2013015I2 (el) 2015-08-05
JP2005529120A (ja) 2005-09-29
PE20040086A1 (es) 2004-04-27
AU2002255017A1 (en) 2003-11-03
JP5142448B2 (ja) 2013-02-13
NO329327B1 (no) 2010-09-27
EP1505066B1 (de) 2006-12-06
AU2002255017B2 (en) 2008-11-13
IL164645A (en) 2010-11-30
CY1107564T1 (el) 2013-03-13
CZ20041122A3 (cs) 2005-03-16
WO2003089425A1 (es) 2003-10-30
IL164645A0 (en) 2005-12-18
CZ305162B6 (cs) 2015-05-27
NO20044999L (no) 2005-01-14
EP1505066A1 (de) 2005-02-09
BG108941A (en) 2005-12-30
UA76866C2 (uk) 2006-09-15
KR100673140B1 (ko) 2007-01-22
SK288052B6 (sk) 2013-03-01
MXPA04010313A (es) 2005-06-08
ES2278018T3 (es) 2007-08-01
DK1505066T3 (da) 2007-03-19
BG66302B1 (bg) 2013-03-29
HK1072772A1 (en) 2005-09-09
HRP20041048A2 (en) 2005-02-28
AR039423A1 (es) 2005-02-16
CY2013015I1 (el) 2015-08-05
BRPI0215703B8 (pt) 2021-05-25
DE60216641D1 (de) 2007-01-18
BR0215703A (pt) 2005-02-01

Similar Documents

Publication Publication Date Title
ATE347550T1 (de) Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure
NO2017035I1 (no) Nintedanib, 3-Z-{1-(4-(N-((4-metyl-piperazin-1-y-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenylmetylenj- 6-metoksykarbonyl-2-indolinon
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
EE200400019A (et) 1-[4-(5-tsüanoindool-3-üül)butüül]-4-(2-karbamoüülbensofuraan-5-üül)piperasiinvesin ikkloriidi polümorfsed vormid
LTC1480644I2 (lt) Nauji heterocikliniai junginiai, veiksmingi kaip beta-laktamazės slopikliai
DK2044043T4 (da) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazinhydrobromid som en forbindelse med kombineret serotoningenoptag, 5-ht3 og 5-ht1a-aktivitet til behandling af kognitiv svækkelse
NO20043997L (no) 4-(N-fenylamino)-kinazoliner/kinoliner som tyrokinaseinhibitorer
EP1954683A4 (de) 2-(phenyl- oder heterocyclyl)-1h-phenanthro(9,10-d)imidazole als mpges-1-inhibitoren
SI1870100T1 (sl) Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline
ATE401893T1 (de) Thiophenepyrimidinone als 17-beta-hydroxysteroid dehydrogenase inhibitoren
DE60320933D1 (de) Rho-kinase inhibitoren
DK1482932T3 (da) N3-alkylerede benzimidazolderivater som MEK-inhibitorer
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
EP1828143A4 (de) 2-(phenyl- oder heterocyclyl)-1h-phenantro[9,10,d]imidazole als mpges-1-inhibitoren
IL188207A (en) 1 - [2 - (3-Tret-Butyl Oreido) -3,3-Dimethylbutyril] -4- (7-Methoxy-2-Pyrazole-1-Il-Quinoline-4-Oxyl) -Pyrrolidine-Carboxylic Acid (1 -Cyclopropylamino oxalibutyl) affluent and uses
NO20043642L (no) Heterocykiske tripeptider som hepatitt C inhibitorer
DE60331061D1 (de) Heterozyklische vegfr-2 kinase inhibitoren
NO20070368L (no) Virale polymeraseinhibitorer
DK1838697T3 (da) Fremgangsmåder til at fremstille 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)-piperidin-1-carboxylsyre-derivater og relaterede forbindelser
ATE419250T1 (de) 2-cyanopyrrolidincarbonsäureamide als dipeptidylpeptidase-iv-inhibitoren
DK1713801T3 (da) Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
ATE491692T1 (de) 1-(imidazolin-2-yl)amino-1,2-diphenylethan- verbindungen zur bekämpfung von tierpestkrankheiten
IL180336A0 (en) Crystal forms of (3r) -1 - (2 - methylalanyl - d - tryptophyl) - 3 -(phenylmethyl)-3- piperidinecarboxylic acid 1, 2, 2 - trimethylhydrazide
IS7489A (is) (2-((2-alkoxý)-fenýl)-hringpent-1-enýl) arómatískkarbó- og heteróhringtengd sýra og afleiður
NO20043400L (no) Fremgangsmater for nukleinsyreamplifisering

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1505066

Country of ref document: EP